Dose escalation and expansion study of SAR444200-based regimen in adult participants with advanced solid tumors

Trial Identifier: TCD17240
Sponsor: Sanofi
Start Date: September 2022
Primary Completion Date: December 2025
Study Completion Date: December 2025
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Canada, Ontario TORONTO, Ontario, Canada, M5G 2M9
Canada, Quebec QUEBEC CITY, Quebec, Canada, G1R 2J6
China SHANGHAI, China, 200120
China WUHAN, China, 430022
Korea, Republic of, Seoul-teukbyeolsi SEOUL, Seoul-teukbyeolsi, Korea, Republic of, 06351
Korea, Republic of, Seoul-teukbyeolsi SEOUL, Seoul-teukbyeolsi, Korea, Republic of, 05505
Singapore SINGAPORE, Singapore, 308433
Singapore SINGAPORE, Singapore, 119074
Singapore SINGAPORE, Singapore, 169610
United States, California LOS ANGELES, California, United States, 90033
United States, New York NEW YORK, New York, United States, 10029
United States, Rhode Island PROVIDENCE, Rhode Island, United States, 02903
United States, Texas HOUSTON, Texas, United States, 77030